{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey among nephrologists to understand the perception and usage of Desidustat in CKD patients (Dialysis & Non-Dialysis patients[DND survey])

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. In your clinical practice, what is the % distribution of anemia patients at different stages of CKD? *
    2. Stage II
    %
    Stage III
    %
    Stage IV
    %
    Stage V
    %
  2. What percentage of patients undergo haemodialysis sessions each week according to the timelines mentioned in your clinical practice? *
    3. No of dialysis session % of patients
    Once a week
    %
    Twice a week
    %
    Thrice a week
    %
    More the 3 sessions
    %
  3. In your clinical experience, how prevalent is anemia among patients with chronic kidney disease (CKD)? *

  4. In your clinical practice, when do you start treatment for anemia in patients with chronic kidney disease (CKD)? *

  5. In your opinion, do oral iron supplements help in advanced chronic Kidney disease (CKD) patients undergoing hemodialysis? *

  6. In your clinical experience, under what circumstances do you typically recommend red blood cell transfusions for CKD patients with anemia?*
  7. a. Based on your clinical experience, how frequently do you recommend hemoglobin (Hb) testing for CKD patients *

    8. b. What factors influence your decision on the testing frequency?*
  8. A. Drawing from your clinical experience, could you share what percentage of your dialysis and non-dialysis patients are prescribed Erythropoietin? *
    9. Dialysis (% Patients) Non- Dialysis (% Patients)
    %
    %
    b. What key factors influence your decision to recommend this treatment? *
  9. A. Drawing from your clinical experience, could you share what percentage of your dialysis and non-dialysis patients are prescribed Darbepoetin? *
    10. Dialysis (% Patients) Non- Dialysis (% Patients)
    %
    %
    B. What key factors influence your decision to recommend this treatment? *
  10. Rank the significant risks associated with EPO or ESA treatment in patients with end-stage renal disease and non-dialysis chronic kidney disease.? (Rank 1 to last) *
    11. Rank End Stage Renal Disease Non- Dialysis
    1
    2
    3
    4
  11. In your experience, what are the potential side effects observed during prolonged ESA treatment in your CKD patients? *
    12. A.
    B.
    C.
    D.
  12. Currently in your practice, have you tried any other treatment options other than ESAs in patients with anemia in CKD ? *

  13. What are the 3 most common challenges associated with ESAs? (Multiple choice question)*

  14. What are some compelling reasons for switching a patient from ESA to Desidustat? *

  15. Desidustat has unique MOA of enhancing erythropoiesis by mimicking body’s natural response to hypoxia. In your opinion does it provides edge over MOA of ESAs? *

  16. Choose among the options given, how would you evaluate the safety profile of Desidustat in comparison to Epoetin/ESA *

  17. Choose among the options given, how would you evaluate the effectiveness of Desidustat in comparison to Epoetin/ESA *

  18. Which medication proves to be more cost-effective for long-term use? *

  19. A. Drawing from your clinical experience, could you share what percentage of your dialysis and non-dialysis patients are prescribed Desidustat? *
    20. Dialysis (% Patients) Non- Dialysis (% Patients)
    %
    %
    B. What key factors influence your decision to recommend this treatment? *
  20. Which factor do you consider the most important in determining the dosage of Desidustat for your patients? *

  21. What is your preferred starting dosage of Desidustat for dialysis-dependent CKD patients? *

  22. A) In your clinical practice, how long does it generally takes for a patient to achieve desired HB levels with ESAs? *

    23. B) After achieving the desired level of Hb in your patients, how long you continue the treatment?*

  23. A) In your clinical practice, how long does it generally take for a patient to achieve desired Hb levels with Desidustat? *

    24. B) After achieving the desired level of Hb in your patients, how long you continue Desidustat?*

    C) How often do you make dosage adjustments for Desidustat in your clinical practice? *
  24. What percentage of your patients remain on Desidustat treatment for various durations? *
    25. Duration % Patient
    > 3 months
    %
    > 6 months
    %
    > 9 months
    %
    > 12 months
    %
  25. According to your clinical experience, what specific concerns or limitations do you encounter while prescribing Desidustat to your patients, and how do you address these challenges? *
  26. Which patient can be switched from Desidustat to Epoetin/ESAs? *

  27. Which of the metabolic benefit of Desidustat is observed in your practice? *

  28. Do you agree that your patient has better compliance with Desidustat compared to ESAs? *

  29. What are the major side effects you encounter with Epoetin/ESAs? *

  30. In your opinion, what is a notable clinical advantage of Desidustat in patients with anemia in CKD ? *

  31. Do you use Desidustat in treatment of anemia in post-renal transplant? *

  32. According to you what clinical considerations should guide the initiation and dose adjustment of Desidustat in CKD patients, especially those with comorbidities like diabetes and hypertension? *
  33. In your clinical experience, how does Desidustat influence iron metabolism and the need for iron supplementation in your CKD patients ? *
  34. How do you approach dose titration of Desidustat in patients who show suboptimal hemoglobin response? *
  35. How do you evaluate the cost-benefit ratio of Desidustat in your healthcare setting, especially in comparison to ESAs? *
  36. What is your experience with Desidustat in patients who previously had poor response or intolerance to ESAs? *